Abstract:OBJECTIVE: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions. Antiseizure medications (ASMs) with aromatic ring structure, including carbamazepine, are among the most common culprits. Screening for human leukocyte antigen (HLA) allele HLA-B*15:02 is recommended prior to initiating treatment with carbamazepine in Asians, but this allele has low positive predictive value.METHODS: We performed whole genome sequencing and analyzed 6 199 696 common variants among 113 aromatic ASM-induced SJS/TEN cases and 84 tolerant controls of Han Chinese ethnicity.RESULTS: In the primary analysis, nine variants reached genome-wide significance (p < 5e-08), one in the carbamazepine subanalysis (85 cases vs. 77 controls) and a further eight identified in HLA-B*15:02-negative subanalysis (35 cases and 53 controls). Interaction analysis between each novel variant from the primary analysis found that five increased risk irrespective of HLA-B*15:02 status or zygosity. HLA-B*15:02-positive individuals were found to have reduced risk if they also carried a chromosome 12 variant, chr12.9426934 (heterozygotes: relative risk = .71, p = .001; homozygotes: relative risk = .23, p < .001). All significant variants lie within intronic or intergenic regions with poorly understood functional consequence. In silico functional analysis of suggestive variants (p < 5e-6) identified through the primary and subanalyses (stratified by HLA-B*15:02 status and drug exposure) suggests that genetic variation within regulatory DNA may contribute to risk indirectly by disrupting the regulation of pathology-related genes. The genes implicated were specific either to the primary analysis (CD9), HLA-B*15:02 carriers (DOCK10), noncarriers (ABCA1), carbamazepine exposure (HLA-E), or phenytoin exposure (CD24).SIGNIFICANCE: We identified variants that could explain why some carriers of HLA-B*15:02 tolerate treatment, and why some noncarriers develop ASM-induced SJS/TEN. Additionally, this analysis suggests that the mixing of HLA-B*15:02 carrier status in previous studies might have masked variants contributing to susceptibility, and that inheritance of risk for ASM-induced SJS/TEN is complex, likely involving multiple risk variants.

Genetic susceptibility to the cross-reactivity of aromatic antiepileptic drugs-induced cutaneous adverse reactions.

Hla-A*24:02 As A Common Risk Factor for Antiepileptic Drug-Induced Cutaneous Adverse Reactions

Genetic Predictors of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Aromatic Antiepileptic Drugs among the Chinese Han Population

HLA-B*13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?

Potential role of regulatory DNA variants in modifying the risk of severe cutaneous reactions induced by aromatic anti‐seizure medications

HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema

Association Study of Lamotrigine-Induced Cutaneous Adverse Reactions and HLA-B*1502 in a Han Chinese Population

Pilot Association Study of Oxcarbazepine-Induced Mild Cutaneous Adverse Reactions with HLA-B*1502 Allele in Chinese Han Population

Progress on Relation Between Human Leukocyte Antigen Gene and Oxcarbazepine Induced Cutaneous Adverse Drug Reactions

The association between AED-induced cutaneous adverse drug reactions and the HLA-A, -B, and -DRB1 alleles among Caucasian patients: a pilot multicenter study

Research on Susceptible Genes and Immunological Pathogenesis of Cutaneous Adverse Drug Reactions in Chinese Hans

HLA Association with Drug-Induced Adverse Reactions

Association Between HLA-A*3201 Allele and Oxcarbazepine-Induced Cutaneous Adverse Reactions in Eastern Han Chinese Population

Progress in Study on the Association Between HLA Genetic Variation and Adverse Drug Reactions.

Unraveling the genetic link: an umbrella review on HLA-B*15:02 and antiepileptic drug-induced Stevens–Johnson syndrome/toxic epidermal necrolysis

Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China

Levetiracetam-Induced Cutaneous Adverse Drug Reactions Were Not Associated with Hla Genes in A Small Sample of Chinese Patients with Epilepsy

HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients.

HLA-A*02 Alleles Are Associated with Tetanus Antitoxin-Induced Exanthematous Drug Eruptions in Chinese Patients.

Association Between HLA-B∗46:01 and Cutaneous Adverse Drug Reactions in Han Chinese

The association between HLA-B variants and amoxicillin-induced severe cutaneous adverse reactions in Chinese han population